Denali Therapeutics (DNLI) Total Current Liabilities (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Total Current Liabilities of $110.2 million for Q1 2026, up 19.9% year-over-year from $91.9 million in Q1 2025, and up 12.0% quarter-over-quarter from $98.4 million in Q4 2025.
Denali Therapeutics (DNLI) Total Current Liabilities (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Total Current Liabilities for 10 consecutive years, with $110.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 19.9% year-over-year to $110.2 million; the TTM figure through Mar 2026 stood at $110.2 million (up 19.9% YoY), while the FY2025 annual figure was $98.4 million, down 3.77% from the prior year.
- Total Current Liabilities improved to $110.2 million in Q1 2026 per DNLI's latest filing, from $98.4 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $391.1 million in Q1 2023 and bottomed at $69.4 million in Q2 2023.
- Historically, Total Current Liabilities has averaged $167.7 million across 5 years, with a median of $91.9 million in 2025.
- Annual changes were most pronounced in 2022 — Total Current Liabilities surged 577.2% — and 2023, when it slumped 80.26%.
- Denali Therapeutics' Total Current Liabilities stood at $363.9 million in 2022, then tumbled by 78.57% to $78.0 million in 2023, then jumped by 31.07% to $102.2 million in 2024, then dropped by 3.77% to $98.4 million in 2025, then gained by 12.0% to $110.2 million in 2026.
- Business Quant data shows DNLI's Total Current Liabilities at $110.2 million in Q1 2026, $98.4 million in Q4 2025, and $90.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | 90.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90.08 Mn |
| Mar 31, 2026 | 110.16 Mn |
| Dec 31, 2025 | 98.35 Mn |
| Sep 30, 2025 | 90.15 Mn |
| Jun 30, 2025 | 91.06 Mn |
| Mar 31, 2025 | 91.88 Mn |
| Dec 31, 2024 | 102.21 Mn |
| Sep 30, 2024 | 87.09 Mn |
| Jun 30, 2024 | 74.53 Mn |
| Mar 31, 2024 | 82.58 Mn |
| Dec 31, 2023 | 77.98 Mn |
| Sep 30, 2023 | 71.18 Mn |
| Jun 30, 2023 | 69.36 Mn |
| Mar 31, 2023 | 391.08 Mn |
| Dec 31, 2022 | 363.92 Mn |
| Sep 30, 2022 | 360.67 Mn |
| Jun 30, 2022 | 348.16 Mn |
| Mar 31, 2022 | 341.24 Mn |
| Dec 31, 2021 | 378.25 Mn |
| Sep 30, 2021 | 54.25 Mn |